Kamari Pharma

Focus: Kamari Pharma is an early-stage Israeli biotech founded in 2024 focused on TRPV3 inhibitors for rare dermatological and genetic skin disorders. The company is pre-revenue with a portfolio of four Phase 1 programs targeting niche indications.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Kamari Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Kamari Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

KM-001 cream 1% 12 weeks treatment.

Punctate Palmoplantar Keratoderma Type 1

Phase 1

Clinical Trials (1)

NCT05956314Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

Phase 1

Help build intelligence for Kamari Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded company with exclusive TRPV3 inhibitor platform in an underexplored therapeutic area.
Focus on rare genetic skin disorders (Punctate Palmoplantar Keratoderma, Olmsted Syndrome, Lichen Simplex Chronicus) with limited treatment options and potential for accelerated pathways.
Israeli location in Ness Ziona provides access to strong biotech ecosystem and innovation hub.

Watch Out For

Extremely early stage (Phase 1 only, founded 2024) with no revenue, no disclosed funding, and high clinical and commercial risk.
No active hiring currently advertised and minimal public visibility on leadership, funding sources, or clinical trial progress.

Generated by Claude from Kamari Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Serum chemistry

Punctate Palmoplantar Keratoderma Type 1

Phase 1

Clinical Trials (1)

NCT05435638Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases

Phase 1

IMP Application KM-001

Lichen Simplex Chronicus

Phase 1

Clinical Trials (1)

NCT05454462KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)

Phase 1

KM-023

Olmsted Syndrome

Phase 1

Clinical Trials (1)

NCT07090889Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 4 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo